OLIVIA HOCKENJOS: Open Payments
NPI 1174120307 · HAUGHTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,493 in 72 payments from 11 companies in 2025. Trend: 2023 $37 · 2024 $910 · 2025 $1,493
Food & beverage: $1,416Education: $77
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 17 | $445 |
| Ardelyx, Inc. | 14 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $183 |
| ABBVIE INC. | 17 | $180 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $102 |
| Madrigal Pharmaceuticals | 1 | $67 |
| Gilead Sciences, Inc. | 3 | $61 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
Products named: TREMFYA, IBSRELA, ENTYVIO, XIFAXAN, SKYRIZI, RINVOQ, REZDIFFRA, TERLIVAZ.
Industry payments across LA — which companies pay providers there.
